The USPTO grants Stempeutics patent for Stempeucel stem cell medicine
New Delhi, November 1 () Biotechnology firm Stempeutics Research said Friday that the United States Patent and Trademark Office (USPTO) has granted the patent to the company for its innovative Stempeucel stem cell drug to treat ischemia Criticism of the limbs.
Critical limb ischemia is a severe blockage in the arteries that results in reduced blood flow which in turn can result in poor quality of life with a high risk of leg amputation and death.
U.S. Patent UU. It is for the method of treatment of ischemia by the administration of clustered allogeneic mesenchymal stromal cells, Stempeutics Research said in a statement.
Stempeucel is derived from allogeneic clustered mesenchymal stromal cells extracted from the bone marrow of healthy and adult voluntary donors, he added.
This very important patent comes at the right time, just before our planned pre-Drug Research (PreIND) meeting with the US Food and Drug Administration (USFDA), said Stempeutics CEO B N Manohar.
The patent granted by the USPTO is a strong recognition for Stempeutics for its sustained excellence in scientific and clinical work and underlines the global leadership in allogeneic and combined MSC technology, he added. Stempeutics Research, a group company of Manipal Education and Medical Group, seeks to develop novel stem cell medications that address the main unmet medical needs. AKT BAL